Neurocrine Biosciences (NBIX) Tops Q4 EPS by 12c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neurocrine Bio. (NBIX) PT Lowered to $179 at BofA Securities
February 7, 2025 6:08 AM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $179.00 (from $184.00) while maintaining a Buy rating.
The analyst comments "NBIX announced FY24 Ingrezza revenues of $2.31bn (+26% y/y, ours: $2.316bn, cons: $2.32bn). On FY25 outlook, the company guided to FY25 sales of... More
